MMP2 and neoplasm: The tumor targeting of MAHNP-DOX was also confirmed by significantly lower accumulation and a higher IC50 in normal MCF-10 A breast cells, which are HER2 negative and normally have MMP-2 mostly in its inactive form (Figure S4) (Lee et al., 1996).